活動時間: 2026 年 9 月 1 日 – 12 月 31 日
全產品線累計滿額贈禮
活動期間內,購買任意產品,同一客戶/同一實驗室的多筆訂單金額可累計計算。
累計金額達指定門檻後,即可申請兌換對應贈禮;兌換後將扣除相應金額,剩餘金額可繼續累計並再次兌換。
全產品線累計滿額兌換規則:
滿 500 USD
MCE 毛毯
滿 1,000 USD
MCE CeCe Doll
*限部分代理商
滿 2,000 USD
Anker 行充
滿 5,000 USD
Apple Watch
*限部分代理商
滿 20,000 USD
極米投影儀
*限部分代理商
Screening Library 產品加碼優惠
累計購買Screening Library 產品金額達 5,000 USD,除上述滿額贈禮外,可額外獲得 MCE 100 USD 優惠券實體卡,於下次訂單折抵使用。
不限產品線及使用門檻,一個產品僅限使用 1 張優惠券。優惠券不可與其他優惠活動併用。
範例說明:
訂單 A:320 USD + 訂單 B:200 USD = 累計 520 USD 立即兌換 毛毯 1 個(剩餘 20 USD 可繼續累計)
如何參與:
禮品寄送方式
表單提交後將進行資格審核,將於次月初透過 Email 通知並安排禮品寄送。實際到貨時間將依物流配送進度為準。
科研熱門產品
| Hot Research Areas | Product Name | Cat. No | Description | Cited Publications |
|---|---|---|---|---|
| Cancer Research | MG‑132 | HY‑13259 | Proteasome Inhibitor | 2,185+ |
| Rapamycin | HY‑10219 | mTOR Inhibitor | 1,441+ | |
| Ferrostatin‑1 | HY‑100579 | Ferroptosis Inhibitor | 1,715+ | |
| 3‑Methyladenine | HY‑19312 | PI3K Inhibitor | 1,322+ | |
| LY294002 | HY‑10108 | PI3K Inhibitor | 1,199+ | |
| Anti‑Infection Research | Vorinostat | HY‑10221 | HDAC Inhibitor | 171+ |
| Puromycin | HY‑B1743 | Antibiotic | 436+ | |
| Inflammation/Immunology Research | Resatorvid (TAK‑242) | HY‑11109 | TLR4 Inhibitor | 524+ |
| Chloroquine | HY‑17589A | Autophagy/TLRs Inhibitor | 1,304+ | |
| Neurological Disease Research | DAPT | HY‑13027 | γ‑secretase Inhibitor | 169+ |
| SC79 | HY‑18749 | Akt Activator | 334+ | |
| Cardiovascular Disease Research | Yoda 1 | HY‑18723 | Piezo1 Agonist | 113+ |
| Isoprenaline hydrochloride | HY‑B0468 | β‑adrenergic Receptor Agonist | 94+ | |
| Endocrinology Research | Estradiol | HY‑B0141 | Female Sex Hormone | 136+ |
| Hydrocortisone | HY‑N0583 | Steroid Hormone | 89+ |
| Product Category | Cat. No | Product Name | Cited Publications |
|---|---|---|---|
| ADC Related | HY‑15575 | VcMMAE | 97+ |
| HY‑14519 | Methotrexate | 80+ | |
| Recombinant Proteins | HY‑P7118 | TGF beta 1/TGFB1 Protein, Human | 170+ |
| HY‑P7085 | M‑CSF Protein, Mouse | 145+ | |
| Oligonucleotides | HY‑112251 | D‑Lin‑MC3‑DMA | 168+ |
| HY‑112735 | Hexadimethrine bromide | 115+ | |
| Organoid Related Products | HY‑10182 | Laduviglusib | 315+ |
| HY‑K6001 | Basement Membrane Matrix | 21+ | |
| Lipid Nanoparticles | HY‑153229 | Firefly luciferase mRNA‑LNP | 1+ |
| HY‑153231A | eGFP mRNA‑LNP (500 ng/μL) | 1+ | |
| Reference Compound | HY‑13259 | MG‑132 | 2,185+ |
| HY‑17589A | Chloroquine | 1,304+ | |
| Kits | HY‑K0301 | Cell Counting Kit‑8 | 4,118+ |
| HY‑K0010 | Protease Inhibitor Cocktail | 2,067+ | |
| Natural Products | HY‑10219 | Rapamycin | 1,441+ |
| HY‑19312 | 3‑Methyladenine | 1,322+ | |
| Dye Reagents | HY‑D0940 | H2DCFDA | 818+ |
| HY‑D1055 | MitoSOX Red | 312+ | |
| Biochemical Assay Reagents | HY‑D1056 | Lipopolysaccharides | 582+ |
| HY‑Y0320 | Dimethyl sulfoxide | 379+ | |
| Inhibitory Antibodies | HY‑P9907 | Trastuzumab | 66+ |
| HY‑P9905 | Cetuximab | 55+ | |
| Enzyme | HY‑108882 | DNase I, Bovine pancreas | 40+ |
| HY‑E70005A | Collagenase, Type I | 20+ | |
| Isotope‑Labeled Compounds | HY‑117287 | Deucravacitinib | 35+ |
| HY‑B0389A | D‑Glucose‑13C6 | 61+ | |
| GMP Small Molecules | HY‑14648G | Dexamethasone (GMP) | 4+ |
| HY‑10182G | Laduviglusib (GMP) | 2+ | |
| Peptides | HY‑P0175 | 740 Y‑P | 261+ |
| HY‑13948 | Angiotensin II human | 248+ | |
| Antibodies | HY‑P80137 | GAPDH Antibody (YA418) | 31+ |
| HY‑P80450 | GPX4 Antibody (YA399, Rabbit) | 23+ | |
| Reference Standards | HY‑15142R | Doxorubicin (hydrochloride) (Standard) | 3+ |
| HY‑B1625R | Deferoxamine (Standard) | 3+ |
1.Target Discovery & Validation
Protein Expression & Purification
Protein Crystallography
Target Functional Studies
(SPR/MST/ITC)
2.Intelligent Screening
AI-Assisted Screening
Molecular Dynamics Simulation
3.Hit Identification
Targeted Compound Libraries
Target-Based Screening
Phenotypic Screening
HCS
4.Hit-to-Lead
Hit Expansion
SAR Studies
Analog Synthesis
5.Lead Optimization
Lead Optimization
Compound Synthesis
Peptide/PROTAC/ADC Customization
| Product Category | Cat. No | Product Name | Number of Compounds |
|---|---|---|---|
| Screening Libraries | HY‑L001P | Bioactive Compound Library Plus | 32,925+ |
| HY‑L022P | FDA‑Approved Drug Library Plus | 3,665+ | |
| HY‑L035P | Drug Repurposing Compound Library Plus | 6,117+ | |
| HY‑L021P | Natural Product Library Plus | 6,267+ | |
| HY‑L032 | Fragment Library | 41,368+ | |
| HY‑L025 | Anti‑Cancer Compound Library | 11,134+ | |
| HY‑L002 | Anti‑Infection Compound Library | 4,800+ | |
| HY‑L046 | Anti‑Cardiovascular Disease Compound Library | 2,439+ |